For US Trastuzumab Biosimilars, Development Time Did Not Predict Speed To Market

 
• By Sue Sutter
  
Race driver pass the finishing point and motion blur backgroud. 3D rendering - Illustration
Speed to approval does not always equate to speed to market. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics